Variety of eligible individuals: CDEC mentioned the uncertainty in the number of patients with reasonably significant to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are categorized as getting moderate or moderate disease can have a critical bleeding https://hemgenix04826.blue-blogs.com/43256758/5-easy-facts-about-hemgenix-described